Defence Therapeutics Secures $3.9 Million to Boost Biotech Initiatives

Defence Therapeutics ( (TSE:DTC) ) just unveiled an announcement.

Defence Therapeutics Inc. has successfully closed the second tranche of its non-brokered private placement, raising $3.915 million through the issuance of units consisting of common shares and share purchase warrants. The proceeds will be utilized to advance the company’s preclinical and clinical programs and for general working capital. This financial boost is expected to enhance Defence’s capabilities in the biotechnology sector, supporting its ongoing development of next-generation radio-immuno-conjugate and ADC products.

More about Defence Therapeutics

Defence Therapeutics is a publicly-traded, Canadian biopharmaceutical company focused on developing radiopharmaceuticals and antibody-drug conjugates (ADCs) using its proprietary platform and drug delivery technologies. The company is also working on novel immune-oncology vaccines, with its core ACCUM® technology enhancing the precision delivery of these products to target cells, thereby increasing efficacy against diseases such as cancer and infectious diseases.

YTD Price Performance: 92.31%

Average Trading Volume: 23,686

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $36.73M

For detailed information about DTC stock, go to TipRanks’ Stock Analysis page.